Flagellin Epitope Immunotherapy for Stable IBD Remission
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis, are symptomatic and do not provide a cure, as they fail to address the underlying abnormal immune response to microbiota antigens, particularly CD4+ T cell responses to flagellins, leading to chronic inflammation.
Innovation Solution
Administering a polypeptide comprising flagellin T-cell receptor (TCR) epitopes in combination with a metabolic inhibitor to reduce flagellin antigen-specific memory T cells and increase regulatory T cells, thereby modulating the immune response and preventing or delaying disease flares.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current symptomatic treatments are used for IBD, then symptom relief is achieved, but the underlying abnormal immune response to flagellin antigens is not addressed, leading to chronic inflammation and disease relapse
Solution Approach 1:
The patent extracts and targets the specific pathogenic mechanism (flagellin-specific CD4+ T cell response) from the complex IBD disease process. By using flagellin peptides and metabolic inhibitors to selectively deplete this specific T cell population, the treatment addresses the root cause rather than just symptoms, achieving more reliable and sustained remission.
Solution Approach 2:
The patent changes the metabolic parameters of pathogenic T cells by introducing metabolic inhibitors that disrupt their energy metabolism and survival pathways. This parameter change selectively eliminates pathogenic cells while sparing regulatory T cells, providing a mechanism to resolve chronic inflammation without broadly suppressing the immune system.
2Productivity
If broad immunosuppression is used to reduce inflammation, then symptom relief is achieved, but the specific abnormal immune response to flagellin antigens is not targeted, requiring higher doses and longer treatment duration
Solution Approach 1:
The patent applies local quality by targeting the specific metabolic pathways and antigen-specific receptors of pathogenic flagellin-reactive T cells. The treatment has different effects on different T cell populations: it selectively depletes pathogenic effector T cells while preserving or even expanding regulatory T cells, achieving localized immunomodulation rather than broad suppression.
Solution Approach 2:
The patent uses flagellin peptides as intermediaries to deliver the therapeutic effect specifically to pathogenic T cells. These peptides act as antigens that bind to T cell receptors on pathogenic cells, delivering the metabolic inhibitor effect selectively to the target population and minimizing off-target effects on other immune cells.
3Reliability
If the immune system is broadly suppressed to control inflammation, then disease activity is reduced, but the abnormal immune response to microbiota antigens persists, leading to disease relapse
Solution Approach 1:
The patent inverts the conventional approach by not suppressing the immune system broadly, but rather selectively eliminating only the pathogenic subset while preserving and enhancing regulatory cells. This inversion achieves better long-term control by maintaining healthy immune diversity and function while removing only the harmful flagellin-specific pathogenic T cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively depletes pathogenic CD4+ T cells and induces regulatory T cells, reducing inflammation and potentially providing a curative treatment for IBD by targeting the underlying immune response to microbiota antigens.
Implementation Method 1
an agent that reduces flagellin antigen-specific memory T cells and/or increases regulatory T cells in the subject. In some embodiments, the agent that that reduces flagellin antigen-specific memory T cells and/or increases regulatory T cells in the subject is a metabolic inhibitor.
Data Source
AI summary
Provided herein are methods and compositions for treating and preventing inflammatory bowel disease.